A third less insulin loaded onto the device but the same amount of insulin delivered into the lungs. The Cost of Goods Sold improved immensely using .333 less insulin/ dose. If the product ever gets approved the profit margin on the first $4 billion of raw insulin will quickly retire the debt the company has been saddled with by the FDA's second CRL. The profit will also quickly fund the other lines that look promising in the portfolio.

Much has been made about management not taking care of business. I on the other hand believe there would have been an inherent delay in the approval process regardless of whether or not there was an in vitro clinical on the Dreamboat. MannKind never intended to mass produce the MedTone inhaler once they realized the efficiency of the Dreamboat. The MedTone needed to be cleaned Dreamboat does not, you throw it away.

Ask any doctor who treats diabetes what their biggest challenge is in treating diabetes. They will invariably say that compliance is the biggest problem. Once the dose for Afrezza is established compliance becomes a no brainer. If the patients comply it would not surprise me to see a sudy showing Afrezza actually slows down the progression of the disease.